M alonomycin (antibiotic K16) 1 (Fig. 1a) is a secondary metabolite with antiprotozoal and antifungal activity, isolated from Streptomyces rimosus paromomycinus
. In these examples, decarboxylation of the malonyl thioester intermediates provides the thermodynamic driving force for subsequent carbon-carbon bond formation. It is difficult to envisage how this common biosynthetic logic could account for the aminomalonate moiety of malonomycin.
Another metabolite possessing an intact malonic acid moiety is γ -carboxyglutamic acid, derived from carboxylation of Glu residues in vitamin K-dependent (VKD) proteins [5] [6] [7] [8] (Fig. 1c) . The mammalian VKD carboxylase (VKDC), catalysing this transformation, is suggested to deprotonate and oxidize the vitamin K hydroquinone (KH 2 ) co-factor, driving the formation of a strong base (K -) [9] [10] [11] that deprotonates the non-acidic γ -methylene group of Glu, which then attacks CO 2 to give γ -carboxyglutamic acid (Fig. 1c) . The resulting vitamin K epoxide (KO) is recycled back to KH 2 by the KO reductase enzyme (VKOR)-the target of clinically important anticoagulant drugs including warfarin 12, 13 . Proteins with sequence similarity to the mammalian VKDC are found within other domains of life, including bacteria. For example, a Leptospira VKDC orthologue was shown to convert KH 2 to KO, but no carboxylation activity was observed 14 . The function of this and other putative bacterial VKDC remains unknown.
Here, we describe the discovery of a highly unusual biosynthetic pathway to the antibiotic malonomycin. We identified the malonomycin (mlo) biosynthetic gene cluster (BGC) in two S. rimosus strains. Using a combination of bioinformatics, gene editing, complementation and in vitro experiments, we show that a hybrid nonribosomal peptide synthetase (NRPS)-PKS assembly line generates a precursor premalonomycin, possessing an aspartyl residue that is carboxylated by a bacterial VKDC orthologue (MloH), generating the malonic acid moiety of malonomycin. VKDC-like enzymes are shown to be present in other bacterial species, opening the way for the discovery of new carboxylase enzymes and metabolites containing malonic acid.
Results
Identification and analysis of the mlo BGC. First, we sequenced the genomes of two S. rimosus strains, paromomycinus NRRL 2455 and paramyceticus R2374, and located two almost identical BGCs containing the genes mloF and mloG, encoding proteins with similarity to SbnA and SbnB known to transform l-Ser into l-Dap 15 -a precursor of the malonomycin 1 tetramic acid group 3 . The mlo BGC (Fig. 2a and Supplementary Tables 1 and 2 ) possesses a gene mloI, encoding a dual-module NRPS. The first adenylation (A 1 ) domain of MloI is predicted to activate l-Ser, but bioinformatics tools fail to predict the specificity of the second adenylation domain (A 2 ). We propose that MloI A 2 activates l-Asp via the side-chain carboxyl group to generate the Ser-Asp dipeptide 2 (Fig. 2b) . A hybrid PKS-NRPS MloJ is then proposed to introduce malonyl-CoA to give the β -keto thioester 3. The MloJ adenylation domain is predicted to activate l-Dap, which on condensation with 3 would generate β -ketoacyl-Dap thioester 4. Dieckmann cyclization and chain release would afford the tetramic acid-containing precursor 5 (premalonomycin). Finally, α -carboxylation of the aspartyl moiety of 5 would generate 1. Analysis revealed mloH, encoding a putative VKDC-like enzyme, as a candidate for this challenging carboxylation (Supplementary Table 1 ). MloH exhibits low but significant similarity (23% identity and 38% similarity) to the human VKDC.
Key catalytic residues within the human VKDC, including K218 and H160, which are proposed to be involved in vitamin K co-factor deprotonation and substrate glutamyl carboxylation, respectively 16, 17 , are also conserved in MloH ( Supplementary Fig. 1 ). Whereas the human VKDC utilises vitamin K phylloquinone (vitamin K1), bacteria including Streptomyces possess vitamin K menaquinones (vitamin K2), which are mainly used in respiration and ATP generation (Fig. 1c ) [18] [19] [20] . Similar to the human enzyme, MloH is predicted to possess multiple transmembrane domains centred within a conserved horizontally transferred transmembrane (HTTM) domain characteristic of VKDC ( Supplementary  Fig. 1 ). This HTTM domain is horizontally transferred from metazoan VKDCs to bacteria and, to date, the only known function for proteins possessing this HTTM domain is as VKDC enzymes 21 . This suggests that MloH is an integral membrane protein within the S. rimosus cell membrane, and thus carboxylation probably occurs as a final biosynthetic step before malonomycin is exported.
Characterization of the mlo BGC. Both S. rimosus strains were cultivated and analysed for production of malonomycin 1. R2374 gave a much higher yield of 1 (67 mg l -1 ) than NRRL 2455 (2 mg l -1 ), as confirmed by reversed-phase high-performance liquid chromatography (RP-HPLC), liquid chromatography-high resolution mass spectrometry (LC-HRMS) and NMR (Table 1, Supplementary Fig. 2  and Supplementary Table 3) , and was chosen for further studies. To investigate the biosynthesis of 1, mloABDLMN genes were inactivated individually by clustered regularly interspaced short palindromic repeats CRISPR/Cas9 gene editing 22 . Although MloIJ appears to possess all of the domains required for premalonomycin 5 assembly, mloAB encodes two additional NRPS modules, the deletion of which significantly impaired production of 1 ( Supplementary  Fig. 3a) . This, coupled with the presence of a condensation domain, rather than the usual adenylation domain, at the amino (N) terminus of MloI, suggests that MloAB may be a functional component of the assembly line ( Supplementary Fig. 3b,c) , initiating peptide assembly and installing amino acids at the Ser residue of malonomycin precursors that are subsequently cleaved by a protease, as seen for some other NRPS products [23] [24] [25] . To investigate this, the N-terminal MloI condensation domain was deactivated using CRISPR-Cas9 to mutate the catalytic His residue (H146A), which is known to be essential for the activity of condensation domains 26, 27 . The resultant strain produced only a trace amount of 1, similar to the ∆ mloA strain ( Supplementary Fig. 4) . A mloA(S546A) mutation was similarly introduced onto the chromosome, blocking phosphopantetheinylation of the MloA peptidyl carrier protein domain, which also resulted in only a trace amount of 1. In addition, complementation of the ∆ mloA strain with the mloA(S546A) mutant gene failed to restore malonomycin production, whereas complementation of ∆ mloA with mloA restored production to wild-type levels ( Supplementary Fig. 4 ). Given that phosphopantetheinylation of MloA and a catalytically active MloI C 1 -domain are both required for efficient production of malonomycin, it is likely that MloA fulfils a catalytic function, transferring an aminoacyl or peptidyl precursor to MloI via its N-terminal condensation domain, generating a propeptide that is subsequently processed. The observations that the MloA and MloI C 1 domain mutants can still produce trace quantities of 1 suggest that MloI can initiate peptide assembly with l-Ser, albeit very inefficiently.
As malonomycin is exported out of the cell in the wild-type strain, the putative ABC transporter mloD was targeted for inactivation. In the absence of the transporter, it was envisaged that precursors, including propeptides, might accumulate within the cell, allowing their detection. While the resultant ∆ mloD strain showed no evidence of malonomycin or premalonomycin in the fermentation media, LC-HRMS analysis of cellular extracts from ∆ mloD, and also wild-type strains, has so far failed to identify the presence of malonomycin propeptides. However, the possibility that propeptide precursors exist cannot be ruled out.
Of the remaining genes in the mlo cluster, inactivation of either mloL or mloN had no effect on malonomycin production; however, deletion of mloM-a putative LuxR-type transcriptional regulator-abolished production of 1. Complementation of ∆ mloM with constitutively expressed mloM resulted in 5.5-fold enhanced production of 1 (370 mg l ) over the parent strain (Table 1) , confirming MloM is a positive regulator of the mlo BGC.
MloI activates l-Asp via the side-chain carboxyl group. To further elucidate the biosynthesis of malonomycin 1, we explored the specificity and regioselectivity of the MloI A 2 domain, to establish whether l-Asp activation occurs via the side-chain carboxyl (Fig. 3a) . MloI A 2 T 2 didomain was overproduced in Escherichia coli and assayed for adenylation activity 28 . Activity was observed with l-Asp and at a lower level with l-Asn, while the 18 other amino acids including d-Asp showed little or no activity (Fig. 3b) . 18 O-labelled O label from the C4 (side-chain) carboxyl of 9 to adenosine monophosphate (AMP) was observed, but not from the C1 carboxyl of 8 (Fig. 3c) . Although MloI A 2 T 2 shows clear regioselectivity for the C4 carboxyl of l-Asp, the incorporation of 18 O into AMP was low. This may be due to background ATPase activity of the adenylation domain 29 when removed from its native assembly line. For additional confirmation of the MloI A 2 regioselectivity, a second thiolation assay was developed using N-acetylcysteamine (SNAC) to capture Asp from the Asp-AMP intermediate 10 ( Fig. 3a,d) . Analysis of the Asp-SNAC thioesters produced from incubating MloI A 2 T 2 with ATP, SNAC and isotopomers 8 or 9 confirmed that the A 2 domain is highly selective for the l-Asp side-chain carboxyl group, consistent with the proposed pathway (Fig. 2b) . Control experiments carried out with a standard (C1 carboxyl) l-Asp-activating adenylation domain (A 2 ) from the surfactin NRPS (SrfAB) 30 showed the reverse isotopic labelling patterns as expected ( Supplementary Fig. 5 ).
Characterization of the bacterial VKDC orthologue MloH. Next, we deleted the putative VKDC-like enzyme MloH ( Supplementary  Fig. 6a,b) . Production of malonomycin 1 was abolished in the ∆ mloH strain, and two new compounds 5 and 12 were produced at significant titres ( Fig. 4a and Table 1 O enriched at the outset, the SNAC thioester derived from 8 retained > 99% of the 18 O label, whereas thiolation of 9 resulted in around 50% loss of 18 O. Given that only one of the two oxygen atoms of the carboxyl group is labelled and only half of the 18 O can be lost on thiolation, these assays show that MloI A 2 is highly selective (around 99% selective) for the C4 carboxyl group. LC-HRMS data: Asp-SNAC [ Supplementary Table 3) , to thermally decarboxylated malonomycin (8R/S)-5. Complementation of the ∆ mloH strain with mloH restored production of 1 to wild-type levels. Thus, MloH is essential for the carboxylation of the precursor premalonomycin 5, to generate malonomycin 1. NMR experiments confirmed that 5 isolated from ∆ mloH is a single diastereoisomer, whereas the decarboxylated malonomycin (8R/S)-5 is a 1:1 mixture of diastereoisomers ( Supplementary Figs. 7-9 ). Derivatization of the amino acids, derived from hydrolysis of 5, using Marfey's reagent 31 , revealed that 5 from ∆ mloH possesses both l-Ser and l-Asp, confirming the (8S) configuration of 5 ( Fig. 4b and Supplementary Fig. 6e) , consistent with the activation of l-Asp by MloI A 2 T 2 (Fig. 3b) . The other metabolite 12 was shown by LC-HRMS, MS/MS and NMR analysis to be an N-succinylated premalonomycin derivative (Fig.  4 and Supplementary Figs. 10-14) . Succinylation of peptide natural products has been reported, and may modify the biological activity as part of a host self-defence mechanism [32] [33] [34] [35] . However, as no detectable quantity of succinylated 1, and only trace quantities (1 mg l -1 ) of 12 are evident in the wild-type strain, we suggest that premalonomycin 5 accumulates in ∆ mloH, and is adventitiously succinylated by the abundant cellular pool of succinyl-CoA to give the side product 12.
Further evidence that MloH shares a similar catalytic function to the mammalian VKDC was obtained by site-directed mutagenesis. In the human enzyme, K218 and H160 are important for activity 16, 17 .
A K218A mutation results in the loss of co-factor oxidation and γ -Glu carboxylation, suggesting that K218 deprotonates the KH 2 co-factor 16 (Fig. 1c) . Conversely, a H160A mutant showed minimal carboxylation activity, but oxidation of KH 2 to KO was unaffected, suggesting that H160 may help stabilize the reactive γ -glutamyl enolate intermediate during carboxylation 17 . Mutagenesis of the corresponding residues in mloH generated K182A/H/R or H119A/ K/R mutants that were used to complement the ∆ mloH strain. Whereas the ∆ mloH::mloH strain produces 1 at wild-type levels, ∆ mloH::mloH(H119A) failed to restore the production of 1, suggesting that this residue is involved in carboxylation activity ( Table 1) . The K182A mutant reduced the production of 1 to less than 5% of the wild type. The human K218A mutant abolished enzyme activity, but could be rescued with the addition of exogenous amines, which are suggested to deprotonate the KH 2 co-factor in the absence of the general base K218 (ref. 16 ). It is therefore possible that the residual activity of MloH K182A could be a consequence of an alternative cellular amine or water functioning as a base. Substitutions by larger amino acids further reduced (K182H) or abolished (K182R) production (Table 1) . Presumably, in K182R, the side chain is unable to adopt the geometry required to deprotonate KH 2 and also blocks another molecule from functioning as a base. The MloH H116 residue, given its close proximity to H119, was also subjected to mutagenesis. In this case, H116A/K/R mutations all resulted in significant malonomycin production ( Supplementary Fig. 15 ). These results suggest that the conserved K182 and H119 residues of MloH provide the same catalytic functions as the corresponding residues in the related human VKDC.
From BLAST analysis, it is apparent that there are a number of other VKDC-like proteins in bacteria exhibiting high similarity to MloH. One such protein is encoded by orf44 from Nocardia gamkensis NBRC 108242 (52% identity and 64% similarity). The N. gamkensis orf44 is present in a BGC that resembles the mlo BGC ( Supplementary Figs. 3d and 16 ). Unlike the NRRL 2455 and R2374 mlo BGCs, which share > 93% identity, the proteins in the Nocardia BGC exhibit between 40 and 60% identity to the corresponding mlo-encoded proteins. Efforts to isolate malonomycin-like metabolites from N. gamkensis, and from expression of the Nocardia BGC in the heterologous hosts Streptomyces coelicolor and Streptomyces albus, have so far been unsuccessful. However, ORF44 exhibits 52% identity to MloH, so we examined this protein for VKDC-like activity using orf44 to complement ∆ mloH. The resulting strain ∆ mloH::Ng orf44 produced good quantities of 1 (53% of that of the wild-type R2374 (Fig. 4a and Table 1) ), confirming that two VKDC-like enzymes from distinct bacterial genera have the ability to α -carboxylate aspartyl precursors to generate intact aminomalonic acid structures in secondary metabolism.
Conclusion
In summary, a genomics-driven approach has been used to identify the BGC for malonomycin, revealing a bacterial VKDC orthologue (MloH). Through gene knockout and complementation experiments, we showed that MloH is responsible for the α -carboxylation of an aspartyl precursor, generating the intact aminomalonic acid moiety of malonomycin. Site-directed mutagenesis of conserved active-site residues in MloH abolished activity, in line with previously reported effects in the human enzyme, as expected if MloH is a functional orthologue of VKDC. A second bacterial VKDC-like protein from Nocardia was also shown to share functionality with MloH. Additionally, 18 O-labelling experiments showed that l-Asp is activated via its side-chain carboxyl group in an NRPS-PKS assembly line to deliver the premalonomycin precursor for subsequent carboxylation. This work provides functional characterization of VKDC-like enzymes of bacterial origin and reveals a highly unusual pathway to aminomalonic acid-containing metabolites. (1) is observed in the wild-type strain, but is abolished in the VKDC deletion strain ∆ mloH, which produces compounds premalonomycin (5) 
Methods
Materials. Chemical reagents and solvents were purchased from commercial sources (Sigma-Aldrich and Fisher Scientific) and used without further purification unless otherwise stated. Molecular biology enzymes were purchased from New England Biolabs unless otherwise stated. Oligos were synthesized by Sigma-Aldrich.
Nucleotide sequencing and assembly of the S. rimosus R2374 and NRRL 2455 genomes. Sequencing was carried out on an Illumina MiSeq platform using the Illumina V2 500 cycle kit run in 2 × 250 base pair (bp) mode, using around oneeighth of the full-run capacity for each library type. Nextera Shotgun and Nextera Matepair libraries were constructed from high-molecular-weight genomic DNA following the manufacturer's protocols. Reads were processed using an in-house Illumina adapter trimming tool (fastq_miseq_trimmer). Read pairs were then preassembled using FLASH version 1.2.11 (https://ccb.jhu.edu/software/FLASH/). The Nextera Matepair linker sequence was used for splitting of matepair reads (fastq_miseq_trimmer). Processed reads were assembled de novo using Newbler version 3 (Roche). Several assemblies were carried out using either all or subsets of the input dataset, and the best assembly was selected using a score calculated from the scaffold N50, edge count and total number of contigs.
Genome annotation. Coding sequences were predicted ab initio using fgeneSB version 2 (http://www.softberry.com/). Annotation was transferred by a set of in-house PERL scripts from the most representative hits to Kyoto Encyclopedia of Genes and Genomes and Non-Redundant databases. Coding sequences were colour coded according to the hits to the Clusters of Orthologous Groups of proteins functional database. National Center for Biotechnology Information BLAST version 2.2.17 (ref. 36 ) was used for protein database searches. The final annotation results were manually curated using Artemis (version 16) 37 .
Production of malonomycin and derivatives.
Procedures for the production of malonomycin and malonomycin derivatives were adapted from Schipper et al. 3 as follows. A seed culture consisting of 20 ml Tryptone Soy Broth (TSB) media in an Erlenmeyer flask containing a spring was inoculated with 50 μ l of a stock suspension of S. rimosus subspecies paramyceticus R2374 spores. The seed culture was cultivated at 28 °C with 150 r.p.m. agitation for 48 h and subsequently used to inoculate 70 ml malonomycin production medium (malt extract (Oxoid) 18 g l ; pH 8.5) at 1% v/v in 250 ml flasks containing springs. The fermentation cultures were cultivated for 65 h at 28 °C with 150 r.p.m. agitation.
Isolation of malonomycin and derivatives.
Fermentation cultures were centrifuged at 5,000g to pellet the cells. The fermentation supernatant was reduced in volume tenfold under reduced pressure, adjusted to pH 2 with HCl and centrifuged (5,000g for 10 min) to pellet the precipitated media components and organic matter.
Procedures for the isolation of malonomycin and malonomycin derivatives were adapted from Schipper et al. 3 as follows. For the isolation of malonomycin 1 from the wild-type R2374, the supernatant was adjusted to the isoelectric point of malonomycin (pH 2.7) and 4 volumes of methanol were added, before incubating at − 20 °C for 2 h. The precipitated malonomycin was pelleted by centrifugation (5,000g for 10 min at 4 °C), redissolved in H 2 O and adjusted to pH 8.5. The resultant crude extract was loaded over an anion exchange column consisting of DEAE-Sephadex A25 resin pre-swollen in 0.5 M ammonium acetate (pH 8.5). Malonomycin 1 was eluted with a gradient of 0-1 M acetic acid in stepwise 0.1 M increments of 1.5 column volumes each. Fractions were collected and analysed by RP-HPLC (Phenomenex Kinetex XB-C18 column; 4.6 mm × 250 mm; 5 μ m particle size) using the following method: 240, 280 nm ultraviolet absorbance, a 1 ml min −1 flow rate and a gradient of 0-4 min 3% B, 4-8 min 3-80% B, 8.1-10 min 95% B, 10-11 min 95-3% B and 11-14 min 3% B, with mobile phase A consisting of H 2 O + 0.1% formic acid and mobile phase B consisting of methanol + 0.1% formic acid. Fractions containing 1 were pooled and dried under reduced pressure. The resultant pale yellow-brown residue was washed with ice-cold pH 7.0 H 2 O, and 1 precipitated as a white crystalline solid. The liquid was removed after centrifugation and the wet pellet was frozen and lyophilised, yielding 1 (76 mg isolated from 1 l culture).
Isolation of premalonomycin 5 from the ∆ mloH strain was carried out as described above, except anion exchange fractions containing premalonomycin 5 were pooled and dried under reduced pressure, redissolved in H 2 O and passed through a C18 Bondelut (Agilent). The flowthrough and water wash were pooled and lyophilised, yielding a light yellow-brown solid of 5 (46 mg isolated from 1 l culture).
Compound 12 was purified from the ∆ mloH strain by semi-preparative RP-HPLC from the crude extract obtained after precipitation with methanol. A Varian ProStar HPLC with a Phenomenex Gemini C18 column (10 mm × 250 mm; 
Characterization of malonomycin and derivatives. LC-HRMS characterization
of all malonomycin-related compounds was carried out using a Thermo Dionex UltiMate 3000 UHPLC coupled to a Thermo Q Exactive spectrometer with the following method: (Thermo Accucore C18 column, 2.1 mm × 100 mm; 2.6 μ m particle size), a 0.3 ml min −1 flow rate and a gradient of 0-3 min 3% B, 3-6.5 min 3-95% B, 6.5-8.5 min 95% B, 8.5-9 min 95-3% B and 9-12 min 3% B, with mobile phase A consisting of H 2 O + 0.1% formic acid and mobile phase B consisting of methanol + 0.1% formic acid. Multiple-stage mass spectrometry analysis of malonomycin and related compounds was carried out on a Waters ACQUITY UPLC coupled to an LTQ Orbitrap XL with a Phenomenex Kinetex C18 column (2.1 mm × 100 mm; 2.6 μ m particle size) and a gradient as described previously. Fragmentation settings were set as targeted multiple-stage mass spectrometry (iso width = 0. 
Synthesis of N-succinylated regioisomers and characterization of N-succinylpremalonomycin (12).
Premalonomycin 5 (1 mg; 3 μ mol) was treated with succinic anhydride (2.5 mg; 25 μ mol) in 10 mM phosphate buffer pH 6.5 at 21 °C for 16 h, generating two regioisomers of N-succinylated premalonomycin, with succinylation occurring on either the tetramic acid aminomethyl side chain or the amine of the serinyl moiety. The reaction was analysed by RP-HPLC, with co-injection of 12 isolated from the S. rimosus ∆ mloH strain identifying the earlier-eluting regioisomer as the natural product 12. Characterization of the two regioisomers by MS/MS and two-dimensional NMR (COSY and NOESY) revealed the early-eluting peak 12 to be succinylated on the serinyl moiety and the later eluting peak to be succinylated on the tetramic acid moiety.
CRISPR-Cas9 inactivation of mloH and other open reading frames (ORFs).
Inactivation of mloH, encoding a putative bacterial VKDC orthologue, was carried out by in-frame deletion using CRISPR-Cas9 (ref. 22 ). A 102-bp region, encoding putative active-site residues, was targeted for deletion to prevent polar effects on flanking ORFs. A single protospacer insert was generated using primers ZY56F (5ʹ -ACGCATCAGGCGGGAGAGCCACGG-3ʹ ) and ZY56R (5ʹ -AAACCCGTGGCTCTCCCGCCTGAT-3ʹ ), and subsequently inserted into pCRISPomyces-2 using Golden Gate assembly. A 996-bp thiostrepton resistance cassette (tsr) amplified from pIJ6021 using primers ZY59F (5ʹ -GGAGGGAAAG TGCAATGTACCTGATCAAGGCGAATACTTC-3ʹ ) and ZY59R (5ʹ -CTGGAG GGAAACCAGCGTACTGATCATCACTGACGAATCG-3ʹ ) was then inserted using the SnaBI site using HiFi assembly (New England Biolabs), as a selectable marker due to the inherent resistance of S. rimosus R2374 against apramycin (pCRISPomyces-2 selective marker). Finally, homologous regions flanking the 102-bp deletion site were amplified using primers ZY57F (5ʹ -TGCCGCCGGGC GTTTTTTATGGCGGTGTTGACGGGCAGAT-3ʹ ), ZY57R (5ʹ -CATGTTCGCC GGCGGAGTGGTGATGCTGGACAGCCCGGTC-3ʹ ), ZY58F (5ʹ -GACCGGG CTGTCCAGCATCACCACTCCGCCGGCGAACATG-3ʹ ) and ZY58R (5ʹ -TTAC GGTTCCTGGCCTCTAGGCGAGGACTCCGTGCTGGTC-3ʹ ), inserted at the XbaI site using HiFi assembly (generating the construct pCm2-tsr-mloH), and verified by restriction digestion and nucleotide sequencing. To generate the mloH deletion in S. rimosus, pCm2-tsr-mloH was used to transform E. coli ET12567 (pUZ8002) and subsequently introduced into S. rimosus R2374 by conjugation. Exconjugants were picked to soya flour mannitol (SFM) agar plates containing thiostrepton (30 μ g ml −1 ) and cultivated at 30 °C for 2-3 d. Deletion of 102 bp from mloH was verified by colony PCR amplification of the internal region of mloH using primers ZY70F (5ʹ -CCCAGTAGGCGGGCATCATC-3ʹ ) and ZY70R (5ʹ -ACGACTTCTCCCTCGACGGC-3ʹ ). Colonies showing deletion of 102 bp from mloH were further cultivated on SFM at high temperature (37-39 °C) to promote loss of the plasmid. Replica plating on SFM with and without thiostrepton was used to screen for mloH mutants without plasmid. Gene inactivation of other mlo ORFs was carried out similarly, using the primers and plasmids detailed in Supplementary Tables 4 and 5 . For point mutations introduced to the chromosome using CRISPR-Cas9, the target codons were altered on the homologous flanking arms used for DNA repair after Cas9 cleavage. The plasmids were constructed as described previously.
Complementation of the ∆mloH strain and other ORFs. A tsr amplified from pIJ6021 using primers ZY65F (5ʹ -TGAAAAACGCTCACTGGTACCTGATCA AGGCGAATACTTC-3ʹ ) and ZY65R (5ʹ -CAAGCTTAGATCTATGCATGTGA TCATCACTGACGAATCG-3ʹ ) was inserted into the Φ BT1-integrative plasmid pAV11b (a gift from M. Smith at the University of York) at the KpnI site using HiFi assembly, regenerating the KpnI site. The constitutive promoter ermE*p was amplified from pIJ86 using primers ZY72F (5ʹ -TGAAGTATTCGCCTTGATCAG TACCAGCCCGACCCGAGCA-3ʹ ) and ZY72R (5ʹ -AGCCACCAGTGCGTGAT CATATGTCCGTACCTCCGTTGCT-3ʹ ), and mloH (1.5 kilobases) was amplified from S. rimosus R2374 genomic DNA using primers ZY73F (5ʹ -AGCAACGGAG GTACGGACATATGATCACGCACTGGTGGCT-3ʹ ) and ZY73R (5ʹ -GAAAAAC GCTCACTGGTACCTCACCGGACGGGCTCCCCGA-3ʹ ). Both fragments were inserted into the KpnI site of the pAV11b-tsr plasmid using HiFi assembly (New England Biolabs), generating construct pAV11b-tsr-mloH, carrying the wild-type mloH gene under control of the ermE* constitutive promoter. The plasmid was subsequently introduced into the S. rimosus R2374 ∆ mloH strain by conjugation using E. coli ET12567 (pUZ8002). Thiostrepton-resistant exconjugants after overlay with thiostrepton (30 μ g ml −1 ) and nalidixic acid (25 μ g ml −1 ) were picked to fresh SFM agar plates supplemented with thiostrepton and subsequently used to inoculate Tryptone Soy Broth liquid cultures. Genomic DNA was extracted, and successfully complemented colonies were verified by PCR using primers ZY70F and R. Other complementation plasmids for mlo knockout strains were constructed similarly using the primers and plasmids detailed in Supplementary  Tables 4 and 5 .
Site-directed mutagenesis of MloH and other Mlo proteins.
To generate point mutations of putative catalytic residues of the S. rimosus R2374 VKDC, plasmid pAV11b-tsr-mloH used to complement the ∆ mloH strain was subjected to sitedirected mutagenesis using a Q5 site-directed mutagenesis kit (New England Biolabs) with primers K182X F (5ʹ -GGAGTGGCCNNNGTCCGCTACGGC TGG-3ʹ ), where NNN is GCC (K182A), CAC (K182H) or CGC (K182R), and K182X R (5ʹ -GCCGGCGAACATGGTGTACGCGAGG-3ʹ ); H116X F (5ʹ -GG GGCCAANNNGTCCACGCACTC-3ʹ ), where NNN is GCC (H116A), CAC (H116K) or CGC (H116R), and R1 (H116A/K) (5ʹ -CAGCGCACC GGCGTTGACCGC-3ʹ ) or R2 (H116R) (5ʹ -CAGCGCACCGGCGTTGACC-3ʹ ); and H119X F (5ʹ -CACTCCACGNNNTCGGCGCTCTACGC-3ʹ ), where NNN is GCC (H116A), CAC (H116K) or CGC (H116R), and R (5ʹ -GTTGGCCCCC AGCGCACCGG-3ʹ ), to introduce a single codon change at positions K182, H116 or H119, respectively. Mutations were verified by nucleotide sequencing (GATC Biotech) and the plasmids were conjugated into S. rimosus R2374 ∆ mloH using standard procedures. Single-colony exconjugants were picked and selected for on thiostrepton-containing SFM agar plates, and integration of the mutant plasmids was verified by PCR. Construction of the mloA(S546A) complementation plasmid was carried out similarly, except primers S546A F (5ʹ -GGTCACGCGCTGCTGGCGTTCCGC-3ʹ ) and S546 R (5ʹ -GCCCAGGCCGAAGAAGTCCTCGTC-3ʹ ) were used to generate the point mutation, with pAVIIb-tsr-mloA as a template. Additional non-catalytic point mutations to mloH to confirm that mutations did not affect MloH protein structure and activity were made using pAVIIb-tsr-mloH as a template and the primers listed in Supplementary Tables 4 and 5 .
Cloning and purification of recombinant MloA, MloI A 2 T 2 and SrfAB A 2 proteins. The mloA gene was PCR amplified from S. rimosus R2374 genomic DNA using primers mloA-AT F (5ʹ -AAAAAACATATGACAAGCACCCCAGGC GTCGG-3ʹ ) and mloA-AT R (5ʹ -AAAAAACTCGAGACGCGCGGCGTCG ACAGCC-3ʹ ). The PCR product was doubly digested with NdeI and XhoI restriction enzymes and ligated into a similarly digested pET21b vector. The resultant construct pET21b-mloA was used to transform E. coli BL21(DE3) for protein production.
The gene encoding the MloI A 2 T 2 didomain was PCR amplified from S. rimosus R2374 genomic DNA using the primers mloI-A 2 T 2 F (5ʹ -AAAAAACATAT GTACTCGCTGGTCCTGCCCTCGCC-3ʹ ) and mloI-A 2 T 2 R (5ʹ -AAAAAACTCG AGGAAGTCATGCTCGGAAACCTCGTCTTCC-3ʹ ). The resultant DNA product was doubly digested with NdeI and XhoI and ligated into a similarly digested pET21b vector, generating construct pET21b-mloI-A 2 T 2 . The resultant plasmid was used to transform E. coli BL21(DE3) for protein production.
The gene encoding the SrfAB A 2 domain 30 was PCR amplified from genomic DNA extracted from Bacillus subtilis strain 168 using primers SrfAB-A 2 F (5ʹ -AAC TTTAAGAAGGAGATATAATGAACGTTCGGCTGTCTGATGTAG-3ʹ ) and SrfAB-A 2 R (5ʹ -CAGTGGTGGTGGTGGTGGTGGGCCAAGGCCTTGCCTCC-3ʹ ). The DNA fragment was inserted into pET21b (NdeI and XhoI digested) using HiFi assembly (New England Biolabs), generating construct pET21b-srfAB-A 2 , and used to transform E. coli BL21(DE3) for protein production.
For production of recombinant proteins (MloA, MloI A 2 T 2 and SrfAB A 2 ), a single BL21(DE3) colony was used to inoculate a Lysogeny broth (LB) seed culture containing ampicillin (50 μ g ml −1 ) and cultivated at 37 °C overnight, before dilution 100-fold into fresh LB supplemented with ampicillin (50 μ g ml −1 ). Cultures were incubated at 37 °C until an absorbance at 600 nm of 0.6 was reached, whereupon isopropyl β -d-1-thiogalactopyranoside (0.5 mM) was added to induce protein production. The cultures were cultivated for a further 4 h at 30 °C before the cells were harvested by centrifugation (4000g for 10 min). The cell pellets were resuspended in lysis buffer (50 mM Tris pH 8.0, 300 mM NaCl and 10% glycerol) and lysed by sonication (Bandelin Sonoplus; 50% power, 30% cycle, 8 min). Lysates were clarified by centrifugation (10,000g). The supernatants were loaded over Ni-NTA columns and washed with 5 column volumes of wash buffer 1 (50 mM Tris pH 8.0, 300 mM NaCl, 20 mM imidazole and 10% glycerol) and 3 column volumes wash buffer 2 (50 mM Tris pH 8.0, 300 mM NaCl, 60 mM imidazole and 10% glycerol), and the protein was eluted with 5 column volumes of elution buffer (50 mM Tris pH 8.0, 300 mM NaCl, 250 mM imidazole and 10% glycerol). Protein eluates were analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, buffer exchanged into 50 mM Tris pH 8.0, 300 mM NaCl and 10% glycerol, and stored at − 80 °C.
Adenylation domain activity assays. The MloI A 2 T 2 didomain was assayed against a range of substrates including the proteinogenic amino acids, dAsp, β -Ala and succinic acid. Activity was measured in real time using an EnzChek pyrophosphate (PPi) detection assay (Thermo Fisher Scientific), with assays set up as follows: 5 mM dithiothreitol, 1 mM ATP, 10 mM MgCl 2 , 10 μ M MloI, 1 U ml −1 purine nucleoside phosphorylase, 0.03 U ml −1 inorganic pyrophosphatase, 0.2 mM 7-methyl-6-thio-guanosine, 10% glycerol v/v, 50 mM Tris HCl pH 7.5 and 0.1 mM NaN 3 . Reaction mixtures were set up without amino acid substrates and pre-incubated at 25 °C for 2 min, whereupon substrate (1 mM) or H 2 O and PPi (0.5 mM) controls were added and the reaction mixtures were incubated for a further 25 min with agitation in a Synergy HT microplate reader monitoring the absorbance at 360 nm. Relative rates of PPi release were calculated as ∆ A 360 min −1 , and compensated for background absorbance due to enzymemediated ATP hydrolysis by subtracting the absorbance of the negative controls (H 2 O added in place of the substrate). Assays with MloA and SrfAB A 2 were carried out similarly. 18 O]-Asp 9 isotopomer substrates were generated by hydrolysis of the corresponding methyl esters 6 and 7 with Na 18 OH in H 2 18 O (Fig. 3a) . The reactions were dried and redissolved to approximately 25 mM in buffer (50 mM Tris pH 7.5). Assays with MloI A 2 T 2 or SrfAB A 2 were carried out as above. For analysis of 18 O-labelled AMP, reactions were quenched with methanol and centrifuged, and ion-suppressing buffer salts were removed from the reaction mixtures by ion exchange using Phenomenex strata SAX SPE cartridges. Briefly, the supernatants were loaded over SAX SPE cartridges, washed with H 2 O and eluted with 5% formic acid in 10% methanol. Reactions were analysed by LC-HRMS and isotopic ratios were calculated by measuring the ion count for each of the isotope peaks for AMP [ 
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